Method for treating a non-rhinorrhea cholinergic influenced secretion

Abstract

A method and composition for treating a patient suffering from an excessive glandular secretion includes administration to the patient of a therapeutically effective amount of a botulinum toxin type A, B, C, D, E, F and/or G.

What is claimed is:  
     
         1 . A method for treating an excessively secreting cholinergically influenced gland, the method comprising the step of injecting an excessively secreting cholinergically influenced gland, or the local area of the gland, with a botulinum toxin in order to reduce an excessive secretory activity of the gland, wherein the secretion is not a symptom of rhinorrhea.  
     
     
         2 . The method of  claim 1 , wherein the botulinum toxin is botulinum toxin type A.  
     
     
         3 . The method of  claim 1 , wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C, D, E, F and G.  
     
     
         4 . The method of  claim 1 , wherein the botulinum toxin is administered in an amount of between 0.01 units and 5000 units.  
     
     
         5 . The method of  claim 1 , wherein the botulinum toxin is administered in an amount of between 0.01 unit and 500 units.  
     
     
         6 . A method for treating an excessively secreting cholinergically influenced gland, the method comprising the step of injecting an excessively secreting cholinergically influenced gland, or the local area of the gland, with a botulinum toxin type A in order to reduce an excessive secretory activity of the gland, wherein the secretion is not a symptom of rhinorrhea.  
     
     
         7 . A method for treating an excessively secreting gland, the method comprising the step of injecting an excessively secreting gland, or the local area of the gland, with a botulinum toxin in order to reduce an excessive secretory activity of the gland, wherein the secretion is not a symptom of rhinorrhea.  
     
     
         8 . The method of  claim 7 , wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C, D, E, F and G.